# EDGAR Filing Document

**Accession Number:** 0001385818
**File Stem:** 0001437749-25-029726
**Filing Date:** 2025-9
**Character Count:** 18771
**Document Hash:** fb9dc5405a9235fbf77018da2b23e96d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-25-029726.hdr.sgml**: 20250923

**ACCESSION NUMBER**: 0001437749-25-029726

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**REFERENCES 429**: 333-272897

**FILED AS OF DATE**: 20250923

**DATE AS OF CHANGE**: 20250923

**EFFECTIVENESS DATE**: 20250923

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AYTU BIOPHARMA, INC
- **CENTRAL INDEX KEY:** 0001385818
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 470883144
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-290469
- **FILM NUMBER:** 251333708

**BUSINESS ADDRESS:**
- **STREET 1:** 7900 E. UNION AVENUE
- **STREET 2:** SUITE 920
- **CITY:** DENVER
- **STATE:** CO
- **ZIP:** 80237
- **BUSINESS PHONE:** (720) 437-6580

**MAIL ADDRESS:**
- **STREET 1:** 7900 E. UNION AVENUE
- **STREET 2:** SUITE 920
- **CITY:** DENVER
- **STATE:** CO
- **ZIP:** 80237

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AYTU BIOSCIENCE, INC
- **DATE OF NAME CHANGE:** 20150609

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AYTU BIOSCIENCE, INC.
- **DATE OF NAME CHANGE:** 20150609

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Rosewind CORP
- **DATE OF NAME CHANGE:** 20070110

**As filed with the Securities and Exchange Commission on September 23, 2025**

**Registration No. 333-**

<br>**UNITED STATES**<br> **SECURITIES AND EXCHANGE COMMISSION**<br>

**WASHINGTON, DC 20549**

------

**FORM S-8**

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

![aytu20250613_s8img001.jpg](aytu20250613_s8img001.jpg)

**AYTU BIOPHARMA, INC.** 

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **47-0883144** |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |

---

**7900 East Union Avenue, Suite 920**

**Denver, Colorado 80237** 

(Address of principal executive offices, including zip code)

**Aytu BioPharma, Inc. 2023 Equity Incentive Plan**

(Full title of the plan)

------

**Joshua R. Disbrow**

**Chief Executive Officer** 

**Aytu BioPharma, Inc.**

**7900 East Union Avenue, Suite 920**

**Denver, Colorado 80237** 

**(720) 437-6580** 

(Name, address and telephone number, including area code, of agent for service)

------

***Copies to:***

**Anthony W. Epps**

**Joshua B. Erekson**

**Dorsey & Whitney LLP**

**1400 Wewatta Street, Suite 400**

**Denver, Colorado 80202**

**(303) 352-1109**

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer ☐ Accelerated Filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE**

On May 21, 2025, at the 2025 annual meeting of stockholders ("2025 Annual Meeting") of Aytu BioPharma, Inc. (the "Company"), the Company's stockholders approved an amendment (the "Plan Amendment") to the Aytu BioPharma, Inc. 2023 Equity Incentive Plan (the "2023 Equity Incentive Plan"). The Plan Amendment increased the number of shares of common stock, par value $0.0001 per share ("Common Stock") reserved for issuance under the 2023 Equity Incentive Plan by 300,000 shares to bring the total number of shares reserved for issuance under the 2023 Equity Incentive Plan to 500,000 shares, not including unissued shares from available awards under prior plans or any returned shares. The Plan Amendment became effective immediately upon approval by the Company's stockholders. This registration statement on Form S-8 is being filed by the Company for the purpose of registering these 300,000 additional shares of Common Stock as part of the 2023 Equity Incentive Plan and consists of only those items required by General Instruction E to Form S-8.

Previously, the 2023 Equity Incentive Plan of the Company was registered for issuance pursuant to the Registrant's registration statement on [<u>Form S-8 (File No. 333-272897) filed with the United States Securities and Exchange Commission (the</u> <u>"</u><u>SEC</u><u>"</u><u>) on June 23, 2023</u>](http://www.sec.gov/Archives/edgar/data/1385818/000110465923074325/tm2319424d1_s8.htm) (the "Prior S-8 Registration Statement"). Pursuant to General Instruction E of Form S-8, the contents of the above-referenced Prior S-8 Registration Statement is incorporated into this Registration Statement by reference to the extent not modified or superseded hereby or by any subsequently filed document, which is incorporated by reference herein or therein.

------

**EXHIBIT INDEX**

**Item 8. Exhibits**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | | | **Incorporated by Reference**  | **Incorporated by Reference**  | **Incorporated by Reference**  | **Incorporated by Reference**  |
| **Exhibit**<br> **No.** | **Description** | **Filed**<br> **Herewith** | **Form** | **Exhibit No.** | **File No.** | **Filing** <br> **Date** |
| 4.1 | [<u>Certificate of Incorporation effective, June 3, 2015.</u>](http://www.sec.gov/Archives/edgar/data/1385818/000119312515217957/d939908dex31.htm) |  | 8-K | 3.1 | 000-53121 | 06/09/15 |
| 4.2 | [<u>Certificate of Amendment of Certificate of Incorporation, effective June 1, 2016.</u>](http://www.sec.gov/Archives/edgar/data/1385818/000114420416106487/v441568_ex3-1.htm) |  | 8-K | 3.1 | 000-53121 | 06/02/16 |
| 4.3 | [<u>Certificate of Amendment of Certificate of Incorporation, effective June 30, 2016.</u>](http://www.sec.gov/Archives/edgar/data/1385818/000114420416111027/v443180_ex3-1.htm) |  | 8-K | 3.1 | 000-53121 | 07/01/16 |
| 4.4 | [<u>Certificate of Amendment of Certificate of Incorporation, effective August 25, 2017.</u>](http://www.sec.gov/Archives/edgar/data/1385818/000114420417045636/v474281_ex3-1.htm) |  | 8-K | 3.1 | 000-53121 | 08/29/17 |
| 4.5 | [<u>Certificate of Amendment to the Restated of Certificate of Incorporation, effective August 10, 2018.</u>](http://www.sec.gov/Archives/edgar/data/1385818/000121390018010718/f8k081018ex3-1_aytubio.htm) |  | 8-K | 3.1 | 001-38247 | 08/10/18 |
| 4.6 | [<u>Certificate of Amendment to the Restated Certificate of Incorporation, effective May 20, 2020.</u>](http://www.sec.gov/Archives/edgar/data/1385818/000143774924030062/ex_726135.htm) |  | 10-K | 3.6 | 001-38247 | 09/26/24 |
| 4.7 | [<u>Certificate of Amendment to the Restated Certificate of Incorporation, effective December 8, 2020.</u>](http://www.sec.gov/Archives/edgar/data/1385818/000165495420013283/aytu_ex31.htm) |  | 8-K | 3.1 | 001-38247 | 12/08/20 |
| 4.8 | [<u>Certificate of Amendment of Certificate of Incorporation, effective March 22, 2021.</u>](http://www.sec.gov/Archives/edgar/data/1385818/000121390021016775/ea138107ex3-1_aytubio.htm) |  | 8-K | 3.1 | 001-38247 | 03/22/21 |
| 4.9 | [<u>Certificate of Amendment of Certificate of Incorporation, effective January 4, 2023.</u>](http://www.sec.gov/Archives/edgar/data/1385818/000110465923001400/tm231530d1_ex3-1.htm) |  | 8-K | 3.1 | 001-38247 | 01/05/23 |
| 4.10 | [<u>Amended and Restated Bylaws.</u>](http://www.sec.gov/Archives/edgar/data/1385818/000155837022007674/aytu-20220504xex3d1.htm) |  | 8-K | 3.1 | 001-38247 | 05/09/22 |
| 5.1 | [Opinion of Dorsey & Whitney LLP.](ex_832864.htm) | X |  |  |  |  |
| 23.1 | [<u>Consent of Grant Thornton LLP, Independent Registered Public Accounting Firm.</u>](ex_831142.htm) | X |  |  |  |  |
| 23.2 | [Consent of Dorsey & Whitney (included in Exhibit 5.1).](ex_832864.htm) | X |  |  |  |  |
| 24.1 | [<u>Power of Attorney (contained on signature page hereto)</u>.](#poa) | X |  |  |  |  |
| 99.1 | [<u>Aytu BioPharma, Inc. 2023 Equity Incentive Plan.</u>](http://www.sec.gov/Archives/edgar/data/1385818/000110465923074325/tm2319424d1_ex10-1.htm) |  | S-8 | 10.1 | 333-272897 | 06/23/23 |
| 99.2 | [<u>Amendment to the Aytu BioPharma, Inc. 2023 Equity Incentive Plan.</u>](http://www.sec.gov/Archives/edgar/data/1385818/000143774925017989/ex_820825.htm) |  | 8-K | 10.1 | 001-38247 | 05/21/25 |
| 107 | [<u>Filing Fee Table</u>.](ex_831143.htm) | X |  |  |  |  |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Denver, State of Colorado, on September 23, 2025.

---

| | |
|:---|:---|
| **AYTU BIOPHARMA, INC**.  | **AYTU BIOPHARMA, INC**.  |
| By: | /s/ Joshua R. Disbrow |
| Name: Joshua R. Disbrow | Name: Joshua R. Disbrow |
| Title: Chief Executive Officer | Title: Chief Executive Officer |

---

**POWER OF ATTORNEY**

We, the undersigned directors and officers of Aytu Biopharma, Inc. (the "Company"), hereby severally constitute and appoint Joshua R. Disbrow as our true and lawful attorney, with full power to him to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith, and any and all pre-effective and post-effective amendments to said registration statement, and any registration statement filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, in connection with the registration under the Securities Act of 1933, as amended, of equity securities of the Company, and to file or cause to be filed the same, with all exhibits thereto and other documents in connection therewith, with the United States Securities and Exchange Commission, granting unto said attorney full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as each of us might or could do in person, and hereby ratifying and confirming all that said attorney or his substitute or substitutes, shall do or cause to be done by virtue of this Power of Attorney.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated:

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Joshua R. Disbrow |  | September 23, 2025 |
| Joshua R. Disbrow | Chief Executive Officer and Director (*Principal Executive Officer*) |  |
| /s/ Ryan J. Selhorn |  | September 23, 2025 |
| Ryan J. Selhorn | Chief Financial Officer (*Principal Financial and Accounting Officer*) |  |
| /s/ John A. Donofrio, Jr. |  | September 23, 2025 |
| John A. Donofrio, Jr. | Chairman |  |
| /s/ Carl C. Dockery |  | September 23, 2025 |
| Carl C. Dockery | Director |  |
| /s/ Abhinav Jain |  | September 23, 2025 |
| Abhinav Jain | Director |  |
| /s/ Vivian Liu |  | September 23, 2025 |
| Vivian Liu | Director |  |

---

## Exhibit 5.1

**Exhibit 5.1**

September 23, 2025

Aytu BioPharma, Inc.

7900 East Union Avenue, Suite 920

Denver, Colorado 80237

Re: Registration Statement on Form S-8

Ladies and Gentlemen:

We have acted as counsel to Aytu BioPharma, Inc., a Delaware corporation (the "Company"), in connection with a Registration Statement on Form S-8 (the "Registration Statement") filed by the Company with the Securities and Exchange Commission (the "Commission") under the Securities Act of 1933, as amended (the "Securities Act"), relating to an additional 300,000 shares of the Company's common stock, par value $0.0001 per share (the "Shares"), that may be issued pursuant to the Company's 2023 Equity Incentive Plan (the "Plan").

We have examined such documents and have reviewed such questions of law as we have considered necessary or appropriate for the purposes of our opinions set forth below. In rendering our opinions set forth below, we have assumed the authenticity of all documents submitted to us as originals, the genuineness of all signatures and the conformity to authentic originals of all documents submitted to us as copies. We have also assumed the legal capacity for all purposes relevant hereto of all natural persons. As to questions of fact material to our opinions, we have relied upon certificates or comparable documents of officers and other representatives of the Company and of public officials.

Based on the foregoing, we are of the opinion that the Shares, when issued and delivered in accordance with the terms of the Plan, will be validly issued, fully paid and non-assessable.

Our opinions expressed above are limited to the Delaware General Corporation Law.

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement. In giving this consent, we do not admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission thereunder.

---

| |
|:---|
| Very truly yours, |
| /s/ Dorsey & Whitney LLP |

---

AE/JE

## Exhibit 23.1

**Exhibit 23.1**

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We have issued our report dated September 23, 2025, with respect to the consolidated financial statements of Aytu BioPharma, Inc. included in the Annual Report on Form 10-K for the year ended June 30, 2025, which is incorporated by reference in this Registration Statement. We consent to the incorporation by reference of the aforementioned report in this Registration Statement.

/s/ GRANT THORNTON LLP

Denver, CO

September 23, 2025

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **AYTU BIOPHARMA, INC**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Type**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Class Title**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Calculation Rule**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount Registered**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Proposed Maximum Offering Price Per Unit**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Maximum Aggregate Offering Price**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Rate**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount of Registration Fee**  |
| 1 | Equity | Common Stock, par value $0.0001 per share | Other | 300000 | $2.37 | $711000.00 | 0.0001531 | $108.85 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $711000.00  |  | $108.85  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $108.85  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Offering Note** <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1</sup> Pursuant to Rule 416(a) under the Securities Act of 1933, as amended, this registration statement shall also cover any additional shares of common stock, par value $0.0001 per share ("Common Stock") which may become issuable under the Aytu BioPharma, Inc. 2023 Equity Incentive Plan, as amended (the "Incentive Plan"), by reason of any stock splits, stock dividends, recapitalization or any other similar transaction effected without receipt of consideration which results in an increase in the number of the Registrant's outstanding shares of Common Stock. Estimated pursuant to Rule 457(c) and (h) solely for purposes of calculating the registration fee. The proposed maximum aggregate offering price per share and proposed maximum aggregate offering price are based upon the average of the high and low sale prices of the Registrant's Common Stock as reported on The Nasdaq Stock Market LLC on September 17, 2025. Represents 300,000 shares of Common Stock reserved for future issuance under the Incentive Plan.

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---